Multitarget PPARγ agonists as innovative modulators of the metabolic syndrome
A multitarget pharmacologic approach could be advantageous for the therapy of metabolic multiple diseases, such as the metabolic syndrome, which is characterized by metabolic abnormalities associated with diabetes, obesity, hypertension, and increased cardiovascular risk. PPAR receptors play a criti...
Gespeichert in:
Veröffentlicht in: | European journal of medicinal chemistry 2019-07, Vol.173, p.261-273 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | A multitarget pharmacologic approach could be advantageous for the therapy of metabolic multiple diseases, such as the metabolic syndrome, which is characterized by metabolic abnormalities associated with diabetes, obesity, hypertension, and increased cardiovascular risk. PPAR receptors play a critical role in metabolic disorders, affecting glucose and lipid metabolism. Drugs simultaneously targeting PPAR and other validated metabolic targets, represent a promising multitarget approach to combine antihyperglycemic, antihyperlipidemic, and antihypertensive effects. This review offers a survey of recently developed multitarget PPARγ agonists as antidiabetic and antihypertensive drugs.
[Display omitted]
•Metabolic syndrome is multifactorial disorder characterized by hyperglycemia, hypertension, obesity and dyslipidemia.•This review is focused on PPARγ agonists directed toward multiple metabolic syndrome targets.•PPARγ agonism can be successfully combined with potent antidiabetic or antihypertensive effects. |
---|---|
ISSN: | 0223-5234 1768-3254 |
DOI: | 10.1016/j.ejmech.2019.04.030 |